摘要目的:研究高压氧(HBO)治疗急性缺血性脑卒中(AIS)的疗效，并探讨其对患者血清白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)的影响。方法:采用随机数字表法将山西医科大学第一医院2017年1月至2020年1月收治的84例AIS患者均分为观察组(常规治疗+HBO， n＝42)与对照组(常规治疗， n＝42)，比较2组治疗后脂质代谢、血清炎性物质水平、脑部微循环及预后情况。 结果:观察组与对照组治疗后，总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较同组治疗前显著下降，高密度脂蛋白胆固醇(HDL-C)水平均较治疗前显著上升( P<0.05)，且观察组治疗后LDL-C水平显著低于对照组，HDL-C水平显著高于对照组( P<0.05)；2组治疗后，血清IL-1β、IL-6及TNF-α水平均较同组治疗前显著下降，且观察组治疗后以上物质血清水平均显著低于对照组( P<0.05)；观察组及对照组治疗后，健侧颈动脉收缩期流速(Vs)、舒张期末流速(Vd)及平均血流速度(Vm)较同组治疗前均无显著性变化( P>0.05)，2组治疗后，患侧Vs、Vd及Vm均较同组治疗前显著上升( P<0.05)，且观察组治疗后以上指标水平均显著高于对照组( P<0.05)；2组治疗前，日常生活能力(ADL)及神经功能缺损评分差异均无统计学意义(均 P>0.05)，治疗后，2组ADL评分均较同组治疗前显著上升( P<0.05)，神经功能缺损评分均较同组治疗前显著下降( P<0.05)，且观察组治疗后ADL评分显著高于对照组[(73.99±11.15)分 vs.(54.69±12.03)分， P<0.05]，神经功能缺损评分显著低于对照组[(8.64±2.25)分 vs.(12.31±2.03)分， P<0.05]。 结论:HBO治疗能有效改善AIS患者脂质代谢紊乱情况，减轻患者机体炎性反应，改善脑部微循环与神经功能缺损，提高患者日常生活能力，保障治疗效果。

abstractsObjective:To investigate the therapeutic effect of hyperbaric oxygen therapy (HBOT) on acute ischemic stroke (AIS) and its effects on lipid metabolism, serum levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).Methods:A total of 84 AIS patients treated in the First Hospital of Shanxi Medical University from January 2017 to January 2020 were enrolled and divided into observation group ( n=42) and control group ( n=42) by random number table method. The control group received conventional treatment, while the observation group received conventional treatment combined with HBOT. The indicators related to lipid metabolism, the levels of serum inflammatory medicators, brain microcirculation, and prognosis were compared between the two groups. Results:After treatment, the levels of the total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly decreased, and the level of high-density lipoprotein cholesterol (HDL-C) was significantly increased in both groups ( P<0.05); and compared with the control group, the observation group had significantly lower LDL-C level and significantly higher HDL-C level ( P<0.05). After treatment, the levels of serum IL-1β, IL-6, and TNF-α were significantly decreased in both groups, and the three indicators in the observation group were all significantly lower than those in the control group ( P<0.05). The systolic velocity (Vs), diastolic velocity (Vd), and mean velocity (Vm) on the healthy side of carotid artery of the patients in both groups had no significant changes after treatment ( P>0.05), while Vs, Vd, and Vm on the affected side of carotid artery of the patients were significantly increased ( P<0.05), and all of them were significantly higher in the observation group than those in the control group ( P<0.05). Before treatment, the activity of daily living (ADL) score and clinical neurological function deficit (CNFD) score showed no significant difference between the two groups (all P>0.05). After treatment, there was an increase in the ADL scores increased and a decrease in CNFD scores decreased in both groups, and the observation group had significant higher ADL scores and CNFD scores than those of the control group [(73.99±11.15) vs. (54.69±12.03), (8.64±2.25) vs. (12.31±2.03); all P<0.05]. Conclusion:HBOT can effectively reduce the lipid metabolism disorders in AIS patients, alleviate their inflammatory response, improve their brain microcirculation, neurological function deficits, and the activity of daily life, so as to ensure the therapeutic effect.